Baseball all-stars step up for blood-clot awareness

Share this article:
If it's summer, it must be sports marketing season for Big Pharma. Sanofi-Aventis recruited an all-star ensemble of baseball greats for its deep vein thrombosis awareness campaign.

The “DVT Blood Clots: Know The Stats, Know Your Risk” campaign, now in its second year, featured appearances last month by players who have had personal experience with DVT. They include: Padres star Tony Gwynn and the Rockies' Aaron Cook, both of whom have suffered with DTV; Orioles/Yankees great Paul Blair, who lost his 29-year-old son to the disease; pitcher Jim Fregosi, who lost a teammate; and pitcher Phil Niekro, who lost his father.

The campaign, executed by Euro RSCG Life PR, debuted at New York's Shea Stadium, where Niekro threw the first pitch on Fireworks Night. Each day at the All-Star FanFest in Pittsburgh, a different player shared his experiences and talked about risk factors and warning signs. Players also appeared at games in San Diego and Boston, and at hospitals in New York, San Diego and Pittsburgh.

The DVT Blood Clots campaign is unbranded, but Sanofi-Aventis markets Lovenox for protection against blood clots.

Meanwhile, Ortho Biotech turned to basketball great Alonzo Mourning for its kidney
disease awareness campaign. Mourning, whose 2000 diagnosis sidelined him for several years and led to a kidney transplant, will appear in cities nationwide with the “Rebound from Anemia” tour. Ortho Biotech markets Procrit for the treatment of anemia in chronic kidney disease patients who are not on dialysis.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...